In vivo molecular skin fluorescence imaging for noninvasive assessment of atypical nevi and melanoma: A validation trial

SFI demonstrated high sensitivity and specificity for discriminating low-risk from high-risk lesions, representing a promising approach to enhance evaluation of clinically concerning pigmented lesions and reduce unnecessary biopsies.